Investor Relations –

News
Releases

Updates –

News releases.

Nov 16, 2026
Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+/HER2- Advanced Breast Cancer
Faeth will sponsor and conduct a Phase 1b/2 study evaluating PIKTOR, its investigational all-oral combination of serabelisib and sapanisertib, in combination with the investigational medicine giredestrant Faeth retains all rights to PIKTOR; under the agreement, Roche will supply giredestrant for
Read press release
Nov 11, 2026
Faeth Therapeutics to Participate in Upcoming November Investor Conferences
AUSTIN, Texas --(BUSINESS WIRE)--Nov. 11, 2026-- Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that management will participate in the following upcoming investor
Read press release
Nov 9, 2026
Faeth Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 Trial Evaluating PIKTOR in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer
Confirmed Objective Response Rate (ORR) of 33% in efficacy-evaluable patients (12 of 36), and a disease control rate (DCR) of 83% Among patients with a PIK3CA mutation, the confirmed ORR was 44% (7 of 16) Preliminary Kaplan-Meier estimated median progression-free survival (mPFS) of 7.4 months, with
Read press release
Nov 6, 2026
Faeth to Report PIK-201 Phase 2 Data and Host Virtual Event on November 9, 2026
AUSTIN, Texas --(BUSINESS WIRE)--Nov. 6, 2026-- Faeth Therapeutics (Nasdaq: FTH), a clinical- stage biotechnology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will host a virtual event on Monday, November 9 at 8:00 AM ET to
Read press release
Nov 5, 2026
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AUSTIN, Texas --(BUSINESS WIRE)--Nov. 5, 2026-- Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted three new employees options to purchase an aggregate of 68,000 shares of the Company’s common stock in connection with their
Read press release
Nov 3, 2026
Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates
Topline results from the Phase 2 PIK-201 trial in endometrial cancer expected by year-end FDA granted Fast Track designation to PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer Presented preclinical data on PIKTOR in HR+/HER2- breast cancer models at ESMO 2026 AUSTIN, Texas
Read press release
Oct 27, 2026
Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors
Dr. Schayowitz brings nearly 20 years of oncology drug development experience, including development leadership roles at Pfizer Oncology and Tesaro Dr. Schayowitz has led dozens of global development programs and led multiple registration programs through regulatory approval AUSTIN, Texas
Read press release
Oct 23, 2026
Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib
In two preclinical breast cancer xenograft models (abstract #431P), PIKTOR inhibited tumor growth to a comparable or greater extent than intravenous gedatolisib PIKTOR inhibited HR+/HER2- breast cancer xenograft tumor growth in models with and without a PIK3CA mutation, the same population
Read press release
Oct 22, 2026
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AUSTIN, Texas --(BUSINESS WIRE)--Oct. 22, 2026-- Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted three new employees options to purchase an aggregate of 17,000 shares of the Company’s common stock in connection with their
Read press release
Oct 19, 2026
Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026
Poster will characterize the efficacy of PIKTOR as a monotherapy and in combination with fulvestrant, oral SERDs, and CDK inhibitors in preclinical models of breast cancer Poster also includes results from head-to-head comparisons with gedatolisib, another multi-nodal inhibitor of the PI3K-AKT-mTOR
Read press release

All clinical data reflects publicly disclosed results only. Forward-looking statements are subject to risk. See Faeth's most recent Annual Report on Form 10-K for risk factors.

The drug product candidates described on this website are investigational agents that have not been approved by the Food and Drug Administration or any other regulatory authority. Their safety and efficacy have not been established.